Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — Q3 FY2017 Earnings Presentation
13 slides from Vivimed Labs's earnings presentation, Feb 14, 2017
Slide 1: Third Quarter FY2017 Earnings Presentation
Third Quarter FY2017 Earnings Presentation February 14, 2017 Transitioning into the Next Phase of Growth
Slide 2: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed Labs’ future business developments and economic performance. Whil
Slide 3: Transitioning into the Next Phase of Growth
Transitioning into the Next Phase of Growth Leveraging chemistry skills and quality compliant manufacturing platform to scale up custom manufacturing and generic product revenue lines within the API vertical Harvesting blue chip customer base more effectively by introduction of new and competitive p
Slide 4: Performance Highlights
Performance Highlights Q3 FY2017 vs. Q3 FY2016 9M FY2017 vs. 9M FY2016 Net Sales Net Profit Net Sales Net Profit Rs. 3,631 mn Rs. 517 mn Rs. 10,310 mn Rs. 1,070 mn 9.4% +124.7% 2.4% +50.6% 19.6% 23.1% Net Profit Net Profit Margin: Margin: 14.2% 10.4% 80.4% 76.9% Healthcare Specialty Chemicals +730 b
Slide 5: Management Perspectives
Management Perspectives Commenting on the performance, Mr. Santosh Varalwar, Managing Director of Vivimed Labs said: “As you are aware, we have taken a number of strategic initiatives over the last 12-18 months which have now started to bear fruits. Our pharmaceuticals business is going from strengt
Slide 6: Financial Performance
Financial Performance Consolidated financial summary Q3 y-o-y Q2 q-o-q Nine Months y-o-y (Rs. million) FY2017 FY2016 Growth (%) FY2017 Growth (%) FY2017 FY2016 Growth (%) Net Sales 3,631 3,319 9.4% 2,993 21.3% 10,310 10,064 2.4% EBITDA 1,031 613 68.3% 612 68.4% 2,312 1,917 20.6% Margin (%) 28.4% 18.
Slide 7: Performance Discussion
Performance Discussion Q3 FY2017 vs. Q3 FY2016 Revenues increased by 9.4% y-o-y to Rs. 3,631 million o Pharmaceuticals segment recorded a growth of 19.1% y-o-y to reach Rs. 2,894 million. Proceeds on divestment of Klar Sehen of Rs. 400 million (net of expenses) were recognised during the quarter.
Slide 8: Financial Performance
Financial Performance Net Sales EBITDA and Margins 28.4% Rs. Million 20.5% Rs. Million 18.5% 18.1% 14.6% 613 512 668 612 1,031 3,319 3,500 3,686 2,993 3,631 Q3 FY16 Q4 FY16 Q1 FY17 Q2 FY17 Q3 FY17 Q3 FY16 Q4 FY16 Q1 FY17 Q2 FY17 Q3 FY17 EBITDA Margin (%) Net Profit and Margins 14.2% Rs. Million 9.0%
Slide 9: Consolidated Quarterly P&L Statement
Consolidated Quarterly P&L Statement Profit & Loss Statement (Rs. million) Q3 FY16 Q4 FY16 Q1 FY17 Q2 FY17 Q3 FY17 Revenues Net Sales / Income from Operations (Net of Excise Duty) 3,299 3,472 3,668 2,984 3,600 Other Operating Income 20 29 18 9 31 Total Revenues 3,319 3,500 3,686 2,993 3,631 Total ex
Slide 10: Consolidated Segment Performance
Consolidated Segment Performance Q3 y-o-y Q2 q-o-q Nine Months y-o-y (Rs. million) FY2017 FY2016 Growth (%) FY2017 Growth (%) FY2017 FY2016 Growth (%) Segment Revenue 3,600 3,299 9.1% 2,984 20.7% 10,252 9,985 2.7% Specialty Chemicals 706 869 (18.7)% 811 (12.9)% 2,367 2,769 (14.5)% Pharmaceuticals 2,
Slide 11: Key Ratios
Key Ratios FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 H1 FY2017 Net Worth (Rs. million) 1,967 4,748 5,091 5,604 5,592 5,852 6,151 Net Debt (Rs. million) 2,959 5,279 6,414 8,591 9,852 8,618 8,074 Including current maturities of LT Debt Fixed Assets (Rs. million) 2,643 5,953 7,090 8,079 8,135 8,142 8,0
Slide 12: Glossary
Glossary ANDA: Abbreviated New Drug Application API: Active Pharmaceutical Ingredients CEP: Certificates of Suitability to the monographs of European Pharmacopoeia CMO: Contract Manufacturing Organization DMF: Drug Master File FDF: Finished Dosage Formulation GMP: Good Manufacturing Pr
Slide 13: Vivimed Labs Limited
Vivimed Labs Limited (CIN: L02411KA1988PLC009465) Veernag Towers, Habsiguda Hyderabad 500 007 www.vivimedlabs.com Phone: +91 40 2717 6005 / 06 Fax: +91 40 2715 0599 Raja Prasad B. +91 40 2717 6005 Vivimed Labs Limited Rajaprasad.B@vivimedlabs.com Saket Somani / Bijay Sharma +91 22 6169 5988 Churchga